Literature DB >> 28733874

[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].

C-H Ohlmann1, K Miller2, J Gschwend3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28733874     DOI： 10.1007/s00120-017-0464-7

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  3 in total

1.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

2.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

3.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321
  3 in total
  2 in total

1.  [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].

Authors:  P Hammerer; L Manka
Journal:  Urologe A       Date:  2019-10       Impact factor: 0.639

Review 2.  [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].

Authors:  C-H Ohlmann
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.